A time-resolved immunofluorometric assay (trIFMA) for human sex-hormone binding globulin (SHBG) is described in which antibody-coated tubes or microtiter strip-wells and a europium (Eu) chelate-labeled monoclonal antibody are used.The trIFMA sensitivity issimilar to that of other SHBG immunoassays, and other analytical variables compare favorably with an SHBG immunoradiometric assay (IRMA) kit and a steroid binding capacity assay: the interassay coeffIcient of variation (CV) is <8% and the intra-assay CV is <6% for concentrations between 6 and 200 nmol/L. The reference intervals (means ± SD) for SHBG concentrations (nmol/L) in serum from 10 men, 10 women, and 10 pregnant women were 23 ± 12, 65 ± 39, and 439 ± 122, respectively.In 14 hirsute women the mean ± SD serum SHBG concentration (37 ± 21 nmol/L) was significantly lower (P <0.01) than the mean for an age-matched, nonhirsute female comparison group. The trlFMA is technically simple, requires no centrifugation or separation reagent, and takes a counting time of only 1 s. In addition, the Eu-label is nontoxic, presents no waste-disposal problems, and has a long shelf life. Fractions containing the labeled antibody were pooled and DTPA-purifled bovine serum albumin was added to give a final concentration of 10 g/L. The pool, ifitered through a 0.2-.an sterile ifiter and stored at 4#{176}C, was usable for at least nine months. With this labeling procedure, about 10 molecules of Eu were attached per antibody molecule.
for SHBG appear to be of equal or superior sensitivity and precision, but their use has been limited by the instability of pure S}{BG and by problems associatedwith its radioiodination (11, 12). Attention has therefore been focused on development of immunometric assays involving labeled antibodies (14-16). Ideally, the label should be nonhazardous, provide a good signal-tonoise ratio, and have a long shelf life. The introduction of lanthanide chelates to generate labeled fluorescent probes
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Nonstandard abbreviations: SHBG, sex-hormone binding globulin (also known as testosterone-estradiol binding globulin and sexsteroid binding protein); trIFMA, time-resolved immunofluorometric assay; IRMA, immunoradiometric assay; DTPA, diethylenetriaminepentaacetic acid; and DHT, 5a-dihydrotestosterone (17-hydroxy-5a-androstan-3-one). promises to satisfy these criteria (17) , and we have therefore used a chelated europium (Eu) label to develop a timeresolved imniunofluorometric assay (trIFMA) for routine determination of SHBG concentrations in blood samples.
Received March

MaterIals and Methods
Materials.
The assay buffer was Tris HC1(50 mmol/L, pH 7.75) containing,per liter, 9 g of NaC1, 5 g of bovine serum albumin, 0.5 g of sodium a.zide, 0. SHBG for 5a-dihydrotestosterone (DHT) was determined by a saturation-analysis method, which relies on the use of 3H-labeled DHT as tracer and dextran-coated charcoal as separation reagent (19) . The SHBG binding capacity (nmol/L) was calculated from the amount of [3H]DHT specifically bound to SHBG after correction for sample dilution, with no correction for dissociation of the [3HIDHT-SHBG complex during the separation step, which was <5%.
SHBG immunoradiornetric assay (IRMA).
For comparison, the concentration of SHBG in serum samples was also determined with a commercially available kit (Farmos Diagnostica Ltd.) based on a liquid-phase IRMA (15) . The assay was performed without modification according to the manufacturer's instructions.
SHBG trIFMA. Dilute serum standards, control sera (low and high concentrations), and samples 100-fold (400-fold for pregnancy sera) in assay buffer and vortex-mix. Pipet duplicate 25-pL aliquots of the diluted standards and samples 
Results
Specificity. The specificity and other characteristics of the monoclonal antibody used in the present assay have been described previously (15, 18) . In an additional test, we heated a specimen of pregnancy serum at 60#{176}C for up to 90 mm, then compared the DHT-binding capacity (19) and trIFMA measurements at various times with the results obtained for the unheated serum. The parallel time-dependent decrease in the values obtained by both assays indicated that the trIFMA measures only SHBG molecules that retain their steroid-binding activity (Figure 1) .
Sensitivity. Whether strip-wells or tubes are used, the sensitivity (least detectable amount) of the IFMA for SHBG, defined as the point equivalent to the mean + 3 SD antibody bound (counts/s) at zero ligand concentration, is 8 pmol per liter of diluted serum sample, equivalent to 0.2 fmol per assay well or tube. Figure 2 illustrates a typical doseresponse curve and precision profile (based on strip-wells). Use of the same Eu-labeled antibody solution in wells and tubes gave a 30% lower final signal (controls) in the tubes. However, the slopes of the standard curves were practically identical. When tubes were used, imprecision (CV) remained <5%.
Analytical recovery. Known volumes of a pregnancy serum pool containing 254 nmol of SHBG per liter were added to a serum sample containing a low (9 nmol/L) concentration Precision. To assess the intra-assay variability of the trIFMA with strip-wells, we made repeated duplicate measurements (n = 10) of serum samples containing low (10-24 nmol/L, n = 6), medium (31-89 nmol/L, n = 11), or high (111-156 nmoL'L, n = 9) concentrations of SHBG. The mean CVs for these three groups were 4.8%, 5.2%, and 5.8%, respectively. Inter-assay (n 10) CVs of measurements of the same samples were 6.4%, 5.1%, and 7.3%, respectively. Precision data were essentially identical when tubes were used.
Measurements of SHBG in serum.
The concentrations of SHBG in serum for healthy men, women, and women during pregnancy are summarized in Table 1 
Discussion
The simplicity and speed of the trIFMA make it ideal for quantifying serum SHBG in clinical laboratories. In comparison with an established IRMA for SHBG (15) , the need for second-antibody separation is obviated by coating the assay tubes or wells with an excess of rabbit anti-SHBG antibodies. By thus "catching" the SHBG-Eu-labeled monoclonal antibody complexes that form during the incubation, one can replace a centi-ifugation step with a more rapid and cost-effective step of washing/aspiration or decantation to separate the free from the bound complexes.
The excellent signal-to-noise ratio obtained in the tr1FMA contributes to the high sensitivity and precision of the assay. Although the low concentrations measurable in this assay (0.2 ftno]Jassay well or tube) are not required for routine analyses of SHBG concentrations in blood samples, it may prove valuable for studies of SHBG production in cell cultures, or for measurements in other body fluids or tissues.
Other characteristics of the trIFMA compare favorably with those of established immunochemical and steroid binding capacity assays for SHBG. Moreover, it appears that, like the IRMA (15) , the trIFMA detects only SHBG molecules that possess steroid binding activity. In addition to estrogen, one of the most potent inducers of hepatic SHBG synthesis is thyroid hormone (21) . Thus some laboratories also advocate the use of serum SHBG measurements as an index of thyroid hormone action, and claim that it is especially useful in the diagnosis of familial thyroid hormone resistance (23) .
Measurements
In comparison with the use of radiolabeled tracers, the chelated Eu-labeled monoclonal antibody is nontoxic, presents no waste-disposal problems, and has a relatively long shelf life. Moreover, because of its stability, large batches of this reagent may be prepared at one time. This is particularly advantageous, eliminating the constant task of performing radioiodinations and the costly disposal of radioactive waste.
We conclude that this trIFMA of SHBG will be a useful addition to the growing number of time-resolved immunoassays being developed for clinical use. In particular, it should provide a valuable adjunct to immunoassays of circulating testosterone and estradiolconcentrations, for clinical evaluations of the bioavailability of these hormones in patients who present with symptoms of inappropriate sex-steroid hormone activity.
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